中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

恩替卡韦治疗乙型肝炎肝硬化患者48周前后血清补体的变化

张雪华 李仲平

引用本文:
Citation:

恩替卡韦治疗乙型肝炎肝硬化患者48周前后血清补体的变化

详细信息
  • 中图分类号: R512.62

Changes in serum complement components after 48 weeks of entecavir treatment in hepatitis B cirrhosis patients

  • 摘要:

    目的观察血清补体C3、C4在恩替卡韦治疗乙型肝炎肝硬化48周前后的变化,探讨恩替卡韦对乙型肝炎肝硬化患者补体的影响。方法 98例乙型肝炎肝硬化患者接受恩替卡韦治疗(10 mg口服,1次/d)48周,其中50例失代偿期肝硬化和48例代偿期肝硬化患者,以50例健康者为对照。98例乙型肝炎肝硬化患者按照HBV DNA载量分为三组:低度组(103~105IU/L),中度组(105~107IU/L),高度组(≥107IU/L)。根据应答情况分为:完全应答[ALT正常,HBV DNA降低至检测下限(<1000 IU/L)和乙型肝炎e抗原(HBeAg)血清转换];部分应答(有1项或2项完全应答);无应答(没有任何1项完全应答)。检测治疗前后补体C3、C4及ALT水平。通过配对t检验比较患者的治疗前后补体C3、C4的水平,两组间比较采用t检验,多组之间比较采用单因素方差分析。结果治疗前各组患者补体C3、C4低于正常对照组(P<0.01),失代偿组低于代偿组(P<0.01),补体C3在低度组最低(P<0.05)、在完全应答组高于部分应答组(P<0.01);治疗后补体C3、C...

     

  • [1] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :Ⅰ-ⅩⅥ. (in Chinese) 中华医学会肝病学分会, 感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :Ⅰ-ⅩⅥ.
    [2]Xie Q, Gui HL.Antiviral treatment for hepatitis B virus related liv-er cirrhosis[J].Chin J Hepatol, 2006, 14 (11) :837-838. (in Chinese) 谢青, 桂红莲.乙型肝炎病毒相关肝硬化的抗病毒治疗[J].中华肝脏病杂志, 2006, 14 (11) :837-838.
    [3]Xiang W, Zhang XL, Ding X, et al.Research progress in transgenic model of hepatitis B virus infection[J].Int J Virol, 2012, 19 (2) :80-83. (in Chinese) 向维, 张薛磊, 丁馨, 等.乙型肝炎病毒感染基因转染模型研究进展[J].国际病毒学杂志, 2012, 19 (2) :80-83.
    [4]Hache C, Villeneuve JP.Lamivudine treatment in patients with chronic hepatitis B and cirrhosis[J].Expert Opin Pharmacother, 2006, 7 (13) :1835-1843.
    [5]Xu Y, Xue BY.A study of integrated traditional Chinese and West-ern medicine therapy for hepatitis B cirrhosis[J].Jilin J Tradie Chin Med, 2011, 31 (12) :1180-1181. (in Chinese) 许岩, 薛博瑜.中西医治疗乙型肝炎肝硬化研究[J].吉林中医药, 2011, 31 (12) :1180-1181.
    [6]Huang CH, Wan MB, She HY.Immune reconstruction of patients with chronic hepatitis B receiving antiviral therapy[J].Shandong Med J, 2011, 51 (16) :105-107. (in Chinese) 黄春红, 万谟彬, 佘会元.抗病毒治疗对慢性乙肝患者的免疫重建作用[J].山东医药, 2011, 51 (16) :105-107.
    [7]Han GC.Complement receptor and virus infection[J].Foreign Med Sci:Immunol, 2003, 23 (5) :257-269. (in Chinese) 韩根成.补体受体与病毒感染[J].国外医学免疫学分册, 2003, 23 (5) :257-259.
    [8]Chen XR.Molecular mechanism of the regulatory effect of cytokines on synthesis of complement components as acute phase proteins[J].Foreign Med Sci:Immunol, 1999, 22 (1) :21. (in Chinese) 陈晓韧.细胞因子对补体急性时相蛋白合成调控的分子机制[J].国外医学免疫学分册, 1999, 22 (1) :21.
    [9]Gan H, Yang J, Sun P.Research progress in human complement C3[J].Foreign Med Sci:Clin Biochem Med Test, 2004, 25 (6) :519-521. (in Chinese) 甘慧, 杨军, 孙萍.人类补体C3进展[J].国外医学临床生物化学与检验学分册, 2004, 25 (6) :519-521.
    [10]Fan JB, Liu HJ, Zhang Q.Clinical significance of measurement of ser-um complement C3and C4levels in patients with liver disease[J].Int J Lab Med, 2009, 3 (2) :171-173. (in Chinese) 范久波, 刘海菊, 张勤.肝病患者血清补体C 3、C 4水平测定的临床意义[J].国际检验学杂志, 2009, 30 (2) :171-173.
    [11]Wang YB, Chen XQ.Analysis of correlation between serum C3, C4, and CRP levels and TBA level in patients with liver cirrhosis[J].J Clin Hepatol, 2009, 25 (4) :304-305. (in Chinese) 王永柏, 陈学权.肝硬化患者血清C 3、C 4、CRP与TBA水平的相关性[J].临床肝胆病杂志, 2009, 25 (4) :304-305.
    [12]Xu L, Xu GG, Zhang JH.Variations in peripheral blood T lympho-cyte subsets and complement in hepatitis B patients[J].Chin Hep-atol, 2009, 14 (5) :397-399. (in Chinese) 徐烈, 徐国光, 张建华.乙型肝炎患者外周血T淋巴细胞亚群及补体的变化[J].肝脏, 2009, 14 (5) :397-399.
    [13]Zhang HL.Clinical significance of determination of serum prealbumin and C3in liver disease[J].Pract Prevent Med, 2005, 12 (4) :934-935. (in Chinese) 张慧莲.血清前白蛋白与C3检测在肝病中的临床意义[J].实用预防医学, 2005, 12 (4) :934-935.
    [14]Cheng YP, Zu YH, Sun T.The change and clinical significance of CRP、C3in serum of patients with hepatitis[J].J Pract Med Technol, 2007, 14 (35) :4816-4817. (in Chinese) 程玉萍, 许亚辉, 孙婷.病毒性肝炎患者血清CRP和补体C3的变化及其意义[J].实用医技杂志, 2007, 14 (35) :4816-4817.
    [15]Liu J, Deng ZD, Wu Y.The clinical study of spontaneous decrease of HBV DNA level in chronic hepatitis B and posthepatitic cirrhosis patients[J].New Chin Med, 2008, 39 (8) :501-503. (in Chi-nese) 刘静, 邓子德, 吴越.慢性乙型病毒性肝炎和肝炎后肝硬化患者HBVDNA水平自发性下降的临床研究-附264例报告[J].新医学, 2008, 39 (8) :501-503.
    [16] Wang ZL, Li Q, Zhang M, et al.Correlation between liver injury and levels of interleukin-18, transforming growth factor-β1, and HBVDNA in patients with chronic hepatitis B[J].Chin J In-fect Dis, 2008, 26 (9) :542-546. (in Chinese) 王珍丽, 李群, 张民, 等.慢性乙型肝炎患者白细胞介素-18, 转化生长因子β1, HBVDNA与肝脏损伤的关系[J].中华传染病杂志, 2008, 26 (9) :542-546.
    [17]Zhang Z, Zou ZS, FU JL, et al.Severe dendritic cell pertur-bation is actively involved in the pathogenesis of acute-on-chronic hepatitis B liver failure[J].J Hepatol, 2008, 49 (3) :396-406.
    [18]Zhang Z, Zhang H, Chen D, et al.Response to interferon-alpha treatment correlates with recovery of blood plasmacy-toid dendritic cells in children with chronic hepatitis B[J].J Hepatol, 2007, 47 (6) :751-759.
    [19]Zhang Z, Zhang JY, Wherry, et al.Dynamic programmed death 1expression by virus-specific CD8T cells correlates with the outcome of acute hepatitis B[J].Gastroenterology, 2008, 134 (7) :1938-1949.
    [20]Chen J, LI LP, Yang C.Progress of therapy and immune re-sponse induced by hepatitis B virus infection[J].Med Reca-pitulate, 2007, 13 (13) :169-369. (in Chinese) 陈军, 李丽萍, 杨春.乙型肝炎病毒感染引起的免疫应答及治疗进展[J].医学综述, 2007, 13 (13) :961-963.
  • 加载中
计量
  • 文章访问数:  2514
  • HTML全文浏览量:  13
  • PDF下载量:  548
  • 被引次数: 0
出版历程
  • 出版日期:  2013-05-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回